Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors
Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.
Aim(s): To investigate the role of CgB in follow-up of NET patients.
Materials and methods: Two-hundred and twelve patients [167 with midgut (mNETs), 45 pancreatic (pNETs)] with elevated plasma CgB levels were included. Correlations between CgB (normal <150pmol/L), tumor burden and histological grade, as well as its predictive value for radiological progression (RP), were investigated.
Conference: 11th Annual ENETSConcerence (2014)
To read the full abstract, please log into your ENETS Member account.